I think we decided on "going at it alone" because

I think we decided on "going at it alone" because we were/are "alone". I don't think it was a choice. I was surprised to see that historically small biotechs get bought out after some smaller partnership is formed and when the biotech is pre clinical and after P2 trials. It is not typical that partnerships /buyouts form at P1 or after P3. I think cytodyn got this all backwards during the HIV trials. Prior to them monoclodal antibodies were not attractive to BP and by the time they showed what Leronlimab could do they were done with both the p3 combo and p3 investigational mono trials. completely out of sync. if they had chosen to prove the drug in a p2 trial, we would have partnered (likely for cheap) years ago. This would have paved the road for a buyout, but all these other indications would likely be undiscovered. I doubt a BP would even realize there drug could be used for cancer, NASH or Covid.

Fortunately we have many new chances with these indications because they are p2 trials. this leaves a lot of room for BP to pick up the ball and run with it. If they realize the value and pony up the cash. otherwise, we "go at it alone"